P942: DREAMM-9: PHASE I STUDY OF BELANTAMAB MAFODOTIN PLUS STANDARD OF CARE IN PATIENTS WITH TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA. (23rd June 2022)

• Record Type: Journal Article
• Authors: Usmani, S. Z.; Mielnik, M.; Koh, Y.; Alonso Alonso, A.; Leleu, X.; Quach, H.; Min, C.-K.; Janowski, W.; Abdallah, A.-O.; Garg, M.; Sandhu, I.; Ocio San Miguel, E. M.; Oriol, A.; Rodriquez-Otero, P.; Ramasamy, K.; Weisel, K.; Besemer, B.; Cavo, M.; Zhou, X. L.; Kaisermann, M. C.; Bego Marques, C. M.; Williams, D.; Carreno, F.; Kremer, B. E.; Gupta, I. V.; Hus, M.
• Is Part Of: HemaSphere. Volume 6(2022)Supplement 3
• Page Start: 832
• Page End: 833
• Publication Date: 2022-06-23
• Subjects: Hematology -- Periodicals; 616.15005
• DOI: 10.1097/01.HS9.0000846636.06566.b4
• Languages: English
• ISSNs: 2572-9241